From dose escalation/expansion studies through global pivotal trials, we help biopharma innovators anticipate challenges to execute oncology & hematology clinical research at the speed of science.
We combine strategic insight with impeccable execution to address change and incorporate development, regulatory, and commercialization strategies at every step.
VP, Global Therapeutic Area Head, Oncology & Hematology
Adam brings nearly 30 years of experience and a strong record of building high-performing, global teams that drive clinical programs for regulatory approval and commercialization of oncology, hematology, and cell and gene therapy products. He focuses on early engagement and development strategies, aligning medical and operational teams across global programs, and measuring performance and health across projects/programs (KPIs) to deliver exceptional experiences for our clients.
Executive Medical Director
Dr. Dow is a board-certified Medical Oncologist with over 30 years of experience in clinical research and medicine, including classic chemotherapy agents, and modern products like molecular-targeted, checkpoint inhibitors and vaccines. Skilled in solid tumor studies both from a safety and response assessment perspective, Dow has led many FIH and early phase study in a wide variety of relapsed/refractory solid tumors providing not only medical monitoring but a strategic medical disease-oriented approach.
Adam Callahan - Vice President, Global Therapeutic Area Head, Oncology & Hematology
From clinical and scientific to operational roles, we operate as an extension of your team so you can:
Changes in scope, geography, and design are common, but we proactively anticipate change, reduce risk at critical inflection points, and respond rapidly to streamline your path.
Our distinct global presence and regional expertise keep your oncology and hematology clinical research moving wherever you may go.
Our integrated medical, scientific, and operational teams deliver flexible, tailored solutions when you need them — and sometimes before you know you need them.
With flexibility, transparency, and worldwide collaboration, we guide you through inevitable challenges and help you:
Oncology and hematology programs require proactive risk management, agility, and trial design and execution that maximizes speed and certainty at each development phase. Early and often engagement – a hallmark of the Caidya approach – helps refine strategy, improve targeting, and accelerate delivery.
With practical technology solutions, we can drive the identification and enrollment of the right patients to generate necessary data. We also leverage our global reach and strong relationships with Centers of Excellence and other Principal Investigators to identify and activate sites across North America, Europe, South America, and APAC, with distinctive presence in China. Finally, we use registries, genetic testing, liquid biopsies, and advocacy partnerships to help reduce screen fails and boost recruitment to meet study timelines.
Our integrated team of medical, scientific, and clinical development experts understands the intricacies of oncology and hematology studies and aligns with the needs of patients, physicians, and trial sites. Our clinical teams have an average of 10–12 years of oncology/hematology monitoring and program management experience, ensuring continuity and high-quality delivery. We apply operational agility to help sponsors scale trials globally, without sacrificing personalized service.